Aprea Therapeutics to Showcase Progress at Investment Conference
Aprea Therapeutics, Inc. (NASDAQ: APRE), a forward-thinking biopharmaceutical firm based in Doylestown, Pennsylvania, is gearing up for an exciting presentation at the upcoming H.C. Wainwright 27th Annual Global Investment Conference. This significant event will occur in New York, bringing together industry leaders, investors, and innovators from the biopharmaceutical sector.
Event Details for Attendees
The conference is scheduled for September 8-10, with Aprea's management team presenting on September 9 at 3:30 PM ET. The venue for this year’s gathering is the prestigious Lotte New York Palace Hotel, known for its central location and high-profile events. A webcast of the presentation will also be made available, allowing wider access to Aprea's insights into their developmental programs and strategic direction.
Innovative Approaches in Cancer Therapy
Aprea Therapeutics is dedicated to revolutionizing cancer treatment by focusing on the unique vulnerabilities found in cancer cells. This targeted approach aims to deliver powerful therapies that minimize damage to healthy cells, an essential consideration in cancer treatment paradigms. By leveraging specific cancer cell mutations, Aprea seeks to ensure that their therapies effectively eradicate tumors while significantly reducing the side effects often associated with traditional chemotherapy methods.
Lead Programs in Clinical Development
Aprea’s pipeline includes promising candidates such as APR-1051, which is recognized as an oral, small-molecule inhibitor of the WEE1 kinase, and ATRN-119, a macrocyclic small-molecule ATR inhibitor. Both programs are currently undergoing clinical trials aimed at addressing solid tumor indications, with the potential to transform the lives of patients struggling with various forms of cancer.
Commitment to Transparency and Investor Engagement
The company's commitment to keeping its investors updated about its journey is apparent as they actively utilize their investor relations website for disseminating critical nonpublic information. This practice aligns with their obligations under Regulation FD, ensuring that all stakeholders have equal access to information regarding Aprea’s ongoing developments.
Contact Information for Further Inquiries
For those interested in learning more about Aprea Therapeutics and their innovative approaches, Mike Moyer from LifeSci Advisors serves as the main contact for investor relations. He can be reached at mmoyer@lifesciadvisors.com for any inquiries or additional information.
Frequently Asked Questions
What is the focus of Aprea Therapeutics?
Aprea Therapeutics focuses on developing targeted cancer therapies that aim to exploit the unique vulnerabilities of cancer cells while minimizing harm to healthy tissues.
When will Aprea present at the investment conference?
Aprea will present on September 9 at 3:30 PM ET during the H.C. Wainwright Global Investment Conference.
Where can I find the webcast of the presentation?
The webcast will be available for 90 days following the presentation on Aprea's investor page under “News & Events.”
What are the lead programs currently in development at Aprea?
Aprea’s lead programs include APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both aimed at treating solid tumors.
How does Aprea ensure investor transparency?
Aprea utilizes its investor relations website to disclose material information and comply with regulatory requirements regarding nonpublic information.
